Alexion Pharma beats by $0.11, beats on revs; raises guidance for FY14, above consensus
Reports Q3 (Sep) earnings of $1.27 per share, $0.11 better than the Capital IQ Consensus Estimate of $1.16; revenues rose 38.6% year/year to $555.1 mln vs the $544.25 mln consensus. Revenue performance for the quarter reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment.
- Co raises guidance for FY14, sees EPS of $5.15-5.20 vs. $5.02 Capital IQ Consensus Estimate, up from $4.95-5.05 prior guidance;
- Sees FY14 revs of $2.220-2.225 bln vs. $2.2 bln Capital IQ Consensus Estimate, up from $2.18-2.20 bln prior guidance.